D61.818Other pancytopenia

D61.818 is the ICD-10-CM diagnosis code for other pancytopenia. It belongs to category D61 (other aplastic anemias and other bone marrow failure syndromes), block D60-D64 (aplastic and other anemias and other bone marrow failure syndromes) and chapter 3 (diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within D61.81, choose D61.818 (Other pancytopenia) only when documentation doesn't support a more specific option: antineoplastic chemotherapy induced pancytopenia (D61.810) and other drug-induced pancytopenia (D61.811).

As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.

In MS-DRG v44.0, it is part of the grouping logic for DRG 808 (Major Hematological and Immunological Diagnoses Except Sickle Cell Crisis and Coagulation Disorders with MCC, relative weight 2.1705), DRG 809 (Major Hematological and Immunological Diagnoses Except Sickle Cell Crisis and Coagulation Disorders with CC, relative weight 1.2262) and DRG 810 (Major Hematological and Immunological Diagnoses Except Sickle Cell Crisis and Coagulation Disorders without CC/MCC, relative weight 1.075), in MDC 16 (Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as 284.19 (other pancytopenia).